Astria Therapeutics (ATXS) Gross Profit: 2017-2018
Historic Gross Profit for Astria Therapeutics (ATXS) over the last 2 years, with Sep 2018 value amounting to -$10,000.
- Astria Therapeutics' Gross Profit fell 104.00% to -$10,000 in Q3 2018 from the same period last year, while for Sep 2018 it was $150,000, marking a year-over-year change of. This contributed to the annual value of -$100,000 for FY2018, which is 120.00% down from last year.
- According to the latest figures from Q3 2018, Astria Therapeutics' Gross Profit is -$10,000, which was up 69.70% from -$33,000 recorded in Q2 2018.
- In the past 5 years, Astria Therapeutics' Gross Profit registered a high of $250,000 during Q3 2017, and its lowest value of -$149,000 during Q1 2017.
- In the last 2 years, Astria Therapeutics' Gross Profit had a median value of -$33,000 in 2018 and averaged $17,714.
- Examining YoY changes over the last 5 years, Astria Therapeutics' Gross Profit showed a top increase of 74.02% in 2018 and a maximum decrease of 104.00% in 2018.
- Quarterly analysis of 2 years shows Astria Therapeutics' Gross Profit stood at $250,000 in 2017, then slumped by 104.00% to -$10,000 in 2018.
- Its last three reported values are -$10,000 in Q3 2018, -$33,000 for Q2 2018, and -$57,000 during Q1 2018.